Anti-PBRM1 Monoclonal Antibody for WB, IHC-P, ELISA - Q86U86

Core Product Specifications and Parameters

Biological Background: PBRM1 Function and Localization

• PBRM1 (Protein polybromo-1), also known as BAF180, is a subunit of the PBAF (SWI/SNF-B) chromatin remodeling complex that alters DNA-nucleosome topology to regulate transcriptional activation and repression.
• It contains multiple bromodomains that recognize acetylated lysines on histones, facilitating chromatin targeting and gene regulation.
• The protein acts as a negative regulator of cell proliferation, consistent with its tumor suppressor role in various cancers.
• PBRM1 is primarily localized in the nucleus, where it carries out its chromatin-remodeling functions.
• It is widely expressed across human tissues, reflecting its fundamental role in gene regulation.
• Post-translational modifications include acetylation and phosphorylation, which may modulate its activity and interactions.
• Alternative splicing generates multiple isoforms, potentially expanding its functional diversity.

Experimental Guidance and Technical Tips

• The immunogen covers amino acids 530-680, a region within functionally important domains; users should validate reactivity in the relevant sample system.
• For Western blotting, detect a band near 193 kDa; consider using a high-molecular-weight protein marker and optimized transfer conditions.
• In immunohistochemistry (IHC-P), optimize antigen retrieval and antibody dilution using positive control tissues known to express PBRM1.
• For ELISA applications, pair with a suitable detection antibody and validate sensitivity and specificity with recombinant protein standards.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio supports diagnostic manufacturers and research laboratories by supplying validated IVD raw materials, including this PBRM1 monoclonal antibody for chromatin remodeling and oncology research. We offer comprehensive sourcing solutions—from optimized antibody pairs and bulk ancillary reagents to custom procurement of rare-target proteins—streamlining your development from concept to clinic.